# Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

> **NCT05332340** · PHASE1 · COMPLETED · sponsor: **Biozeus Biopharmaceutical S.A.** · enrollment: 12 (actual)

## Conditions studied

- Erectile Dysfunction Following Radical Prostatectomy
- Erectile Dysfunction
- Prostate Cancer
- Radical Prostatectomy

## Interventions

- **DRUG:** BZ371A

## Key facts

- **NCT ID:** NCT05332340
- **Lead sponsor:** Biozeus Biopharmaceutical S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-16
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332340, "Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05332340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*